NCT05182073 2025-12-12
FT576 in Subjects With Multiple Myeloma
Fate Therapeutics
Phase 1 Completed
Clinical Trials
16 trialsNCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT05243342 2025-02-17
A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
Genentech, Inc.
Phase 1 Completed
NCT02918331 2025-02-03
A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT04714372 2024-10-24
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT05679258 2024-06-28
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects
Shanghai Henlius Biotech
Phase 1 Completed
NCT03177460 2024-05-03
Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03311828 2024-03-12
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma
City of Hope Medical Center
Phase 1 Completed
NCT04121260 2023-12-08
A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT04136756 2023-06-15
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Nektar Therapeutics
Phase 1 Completed
NCT04280328 2022-03-11
Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
Corvus Pharmaceuticals, Inc.
Phase 1 Completed
NCT02431208 2021-04-02
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hoffmann-La Roche
Phase 1 Completed
NCT02852837 2020-11-16
Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
Janssen Research & Development, LLC
Phase 1 Completed
NCT03068351 2020-02-07
Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hoffmann-La Roche
Phase 1 Completed
NCT02497378 2019-03-07
A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT02116569 2016-09-26
A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
Phase 1 Completed